tbuckley/cabot-search huggingface dataset:
OP0057 Fluorescence optical imaging in juvenile idiopathic polyarticular disease before and during antirheumatic treatment
Authors: A Klein, G-W Just, SG Werner, I Becker, P Oommen, K Minden, H-E Langer, G Horneff
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Valid detection of inflamed joints is essential for correct classification, therapeutic decisions and assessment of treatment efficacy in juvenile idiopathic arthritis (JIA). <h3>Objectives</h3> Fluorescence optical imaging (FOI) enables visualization of inflammation in arthritis of finger and hand joints and might be used in JIA. <h3>Methods</h3> A 24-week observational study in polyarticular JIA patients newly starting treatment with either methotrexate or a biologic was performed. Patients were evaluated clinically, by ultrasound B–mode, power-Doppler and FOI at baseline, week 12 and 24. <h3>Results</h3> Of 37 patients enrolled, 24 patients started MTX and 13 a biologic for the first time (Etanercept n=11, Adalimumab and Tocilizumab one 1). Composite measures, mean JADAS 10 decreased significantly from 17.7 at baseline to 12.2 and 7.2 at week 12 and 24 respectively and JIA-ACR 30/50/70/100 response rates at week 24 were 85%/73%/50%/27%. In total 1110 joints were examined clinically, 990 by US/PD and 990 by FOI. At baseline/week12/week24 23.6%/16.4%/9.0% joints on hand and fingers were clinically active joints, by US 19.4%/16.1%/11.5% joints showed effusions, 18.8%/12.7% and 9.6% showed synovial thickening and by PD 6.9%/1.8%/5% joints showed hyperperfusion. Any sign of arthritis was detected by US/PD in 24.5%/19.2%and17%. By FOI at 38.7%/29.2%/27.6% showed a signal enhancement in at least one phase. Summarizing all 3 points of time, the highest numbers of signals were detected by FOI with 32% of joints, especially in phase 2 while by US/PD 20.7% and by clinical examination 17.5% were active. A high number of joints (21.1%) had FOI signals but were clinically inactive. 20.1% of joints with signals in FOI did not show effusion, synovial thickening or hyperperfusion by US/PD. Due to the high number of negative results specificity of FOI compared to clinical examination/US/PD was high (84–95%), sensitivity was moderate only. <h3>Conclusions</h3> Improvement upon treatment with either methotrexate or a biologic can be visualized by FOI. FOI and US/PD could detect clinical but also subclinical inflammation. FOI detected subclinical inflammation in higher extent than US. <h3>Disclosure of Interest</h3> None declared
Cumulative Kidney Complication Risk by 50 Years of Type 1 Diabetes: The Effects of Sex, Age, and Calendar Year at Onset
Authors: Tina Costacou, Trevor J. Orchard
Journal: Diabetes Care (2017)

OBJECTIVE A common belief is that only a minority of patients with type 1 diabetes (T1D) develop advanced kidney disease and that incidence is higher among men and lower in those diagnosed at a younger age. However, because few patients with T1D survived to older ages until recently, long-term risks have been unclear. RESEARCH DESIGN AND METHODS We examined the 50-year cumulative kidney complication risk in a childhood-onset T1D cohort diagnosed during 1950–80 (n = 932; mean baseline age 29 years, duration 19 years). Participants comprised 144 who died prior to baseline, 130 followed with periodic surveys, and 658 followed with biennial surveys and a maximum of nine examinations for 25 years. Micro- and macroalbuminuria were defined as an albumin excretion rate of 20–199 and ≥200 μg/min, respectively, and end-stage renal disease (ESRD) was defined as dialysis or kidney transplantation. Cumulative incidence was estimated at 10-year intervals between 20 and 50 years, duration and compared by calendar year of diabetes onset. RESULTS By 50 years, T1D duration, ESRD affected 60% of the cohort; macroalbuminuria, 72%; and microalbuminuria, 88%. Little evidence existed for declines in cumulative incidence in recent cohorts, except for ESRD (microalbuminuria 3% increase, macroalbuminuria no change; ESRD 45% decrease by 40 years of T1D duration). Onset before age 6 years was associated with the lowest risk; incidence generally did not differ by sex. CONCLUSIONS Some degree of kidney disease in T1D is virtually universal at long durations and not declining, which has major implications for formulating health care and research strategies. ESRD has declined, but continues to affect &amp;gt;25% of the population by 40 years, duration.
Erratum: Corrigendum: S100-alarmin-induced innate immune programming protects newborn infants from sepsis
Authors: Thomas Ulas, Sabine Pirr, Beate Fehlhaber, Marie S Bickes, Torsten G Loof, Thomas Vogl, Lara Mellinger, Anna S Heinemann, Johanna Burgmann, Jennifer Schöning, Sabine Schreek, Sandra Pfeifer, Friederike Reuner, Lena Völlger, Martin Stanulla, Maren von Köckritz-Blickwede, Shirin Glander, Katarzyna Barczyk-Kahlert, Constantin S von Kaisenberg, Judith Friesenhagen, Lena Fischer-Riepe, Stefanie Zenker, Joachim L Schultze, Johannes Roth, Dorothee Viemann
Journal: Nature Immunology (2017)
Abstract 20727: HuR-dependent Angiogenic Factor-Encoding mRNA Stabilization Mediated by {beta}2 Integrin-Engagement in Macrophages during Ischemic and Inflammatory Angiogenesis
Authors: Jian-Ge Zhang, Yasha Modi, Timur Yarovinsky, Jun Yu, Mark Collinge, Themis Kyriakides, William C. Sessa, Jeffrey R. Bender
Journal: Circulation (2010)

Expression of angiogenic factors and recruitment of macrophages play a crucial role in inflammatory angiogenesis. Furthermore, the regulation of stabilization of angiogenic factor-encoding mRNAs pl...
THU0247 The presence of ANTI-RO and ANTI-LA antibodies is associated with tubulointerstitial damage in lupus nephritis
Authors: A Londono Jimenez, WB Mowrey, A Broder
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Moderate-to-severe tubulointerstitial damage (TID) is associated with poor renal outcomes in lupus nephritis (LN) independent of glomerular pathology<sup>1</sup>. Specific antibody profiles associated with TID in LN have not been identified. Unlike glomerular damage, TID is not associated with anti-dsDNA or complement levels<sup>1</sup>. An association between TID and the presence of anti-Ro/La antibodies has been proposed in Sjögren9s syndrome<sup>2</sup>. Whether these antibodies are associated with TID in LN is not known. <h3>Objectives</h3> To study an association between anti-Ro/La antibodies and moderate-to-severe TID in LN. <h3>Methods</h3> We identified all patients who fulfilled ACR and/or SLICC criteria for SLE. Patients were included if they had an index renal biopsy consistent with LN between January 2005 and July 2015 and had complete data on TID and anti-Ro/La. Medical history, demographic and laboratory data were ascertained from chart review. TID was defined as the presence of moderate or severe tubular atrophy and/or interstitial fibrosis from the renal biopsy reports. <h3>Results</h3> of the 157 LN patients, 39 (25%) had moderate/severe TID (Table). As expected, moderate/severe TID was associated with older age, class III/IV±V LN and lower estimated glomerular filtration rate (eGFR) at biopsy. Anti-Ro antibodies were present in 55 (47%) of patients with none/mild TID and 17 (44%) of patients with moderate/severe TID (p=0.74). Both anti-Ro and anti-La antibodies were present in 11 (9%) of patients with none/mild TID vs 11 (28%) of patients with moderate/severe TID (p=0.003). In the logistic regression model adjusted for age, eGFR and LN class, the presence of both anti-Ro and anti-La antibodies was associated with a 3-fold increase in the odds of TID, OR 3.1, 95% CI (1.1–9.1), p=0.04. <h3>Conclusions</h3> The presence of anti-Ro and anti-La antibodies is associated with moderate/severe TID, independent of age, LN class and eGFR. Understanding the role of anti-Ro/La in the mechanisms underlying TID in LN may lead to novel preventive and therapeutic strategies. <h3>References</h3> Yu F, et al. Kidney Int 2010;77:820–9. Francois H, et al. Nat Rev Nephrol, 2016;12(2):82–93. <h3>Disclosure of Interest</h3> None declared
SAT0098 The association between work disability and mental health in rheumatoid arthritis
Authors: A Houssien, S Norton, E Nikiphorou, F Matcham, J Galloway
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Rheumatoid arthritis (RA) is characterised by joint inflammation, resulting in functional impairment. Consequently, it has long been recognised that work disability is common in RA. However, despite significant pharmacological advances in disease control, little is known about contemporary impact upon work. Depression has emerged in recent years as a key comorbidity in RA. In the general population, depression is strongly correlated with work disability <h3>Objectives</h3> To establish the extent to which depression associates with work ability in RA in a cross sectional study. <h3>Methods</h3> Our hospital routinely collects data via an electronic screening interface, which incorporates a series of validated questionnaires, which patients complete via an iPad while waiting for their appointment. The dataset is linked to the clinical record. For this study, cross sectional data were extracted on adults with RA. Question 2 of the Work and Social Adjustment Scale ("Because of my [RA] my ability to work is impaired") was used as a measure or work disability (scale 0–8). Mental health status was collected using the Patient Health Questionnaire-2 (PHQ), with a score≥3 considered a positive screen for depression. <h3>Results</h3> Of 385 patients with RA were included in the analysis. Their demographics are shown in the Table.1 Patients scoring 3 or more on the PHQ had more severe RA (higher DAS/HAQ), but there was no significant difference in age, sex or disease duration. 124 (32%) reported no work disability, with the overall mean score 3.0. Patients screening positive for depression had a significantly lower work ability even after adjusting for available confounders. <h3>Conclusions</h3> There is a significant correlation between depression in RA and work ability, which persists even after accounting for disease severity. The magnitude of association observed was even greater than that seen between physical function and work. Although unmeasured confounding remains likely, these data confirm the link between depression and work in RA. It is likely that the relationship is bidirectional, between depression and work in RA. Beyond the importance of addressing work ability in RA, the results highlight the need for screening and targeting depression as part of routine clinical care beside the holistic approach of mangement. <h3>Disclosure of Interest</h3> None declared
THU0154 Association between plasma lipids, disease activity and PCSK9 levels in RA patients
Authors: M Heslinga, G Lambert, A Thedrez, J Kastelein, M Nurmohamed
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) are at increased cardiovascular risk with contribution of both inflammation and traditional risk factors. Dyslipidemia is an important risk factor and lipid-lowering therapy plays a key role in cardio-preventive treatment. A new class of low density lipoprotein cholesterol (LDL-C) lowering drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9)-inhibitors are now emerging. In view of a lower rate of musculoskeletal side effects these drugs might be preferred over statins in patients with RA. Active inflammation in RA leads to a decline in lipid levels, but the relation between inflammation and PCSK9 levels is unknown. <h3>Objectives</h3> To assess PSCK9 levels in RA patients, and the relationship with lipid levels and disease activity. <h3>Methods</h3> PSCK9 levels were assessed using ELISA in 97 randomly selected patients. Lipid profile assessment comprised TC, HDL-C, LDL-C and triglycerides. Disease activity was assessed using disease activity score of 28 joints (DAS28). <h3>Results</h3> The mean age of RA patients was 54.5 years (± 10.8) and they were predominantly female (74.2%). The mean PCSK9 value in RA patients was 214.75 (± 73.3), which is similar to that in the general population [1]. PCSK9 values were associated with TC (corrected B 22.34, 95% CI 6.80–37.88, p0.005) and triglycerides (corrected B 21.02, 95% CI -0.84–42.89, p0.044) (table 2). 77 patients had low disease activity (DAS28 ≤3.2), 11 patients had medium disease activity (DAS28 &gt;3.2 and ≤5.1) and 20 patients had highly active disease (DAS28 &gt;5.1). Mean PCSK9 values were 213.01, 246.96 and 258.30 ng/mL, respectively. Patients with active disease had a higher PCSK9 level (corrected B 42.555 95% CI 0.769–84.341, p 0.046) compared to patients with low disease activity (table 1). <h3>Conclusions</h3> PCSK9 levels in RA are similar to the general population. RA patients with active disease had higher PCSK9 levels compared to patients with low disease activity. Altogether, PCSK9 inhibitors could be an alternative treatment for dyslipidemia in RA patients who experience side effects of statins, albeit that a formal trial still has to be conducted in this category of patients. <h3>References</h3> Lambert G, Petrides F, Chatelais M et al. J Am Coll Cardiol. 2014 Jun 10;63(22):2365–73. <h3>Disclosure of Interest</h3> None declared
SP0174 Ways of supporting volunteers
Authors: S Ssymank
Journal: Annals of the Rheumatic Diseases (2017)

The promotion of volunteer workers is an indispensable part of the human resources policy of self-help organizations and requires specific concepts. Using the example of the rheumatism league Baden-Württemberg -an organization with 65,000 members, 3,000 volunteers and 10 fulltime employees- there will be shown best- practice examples. A successful concept covers the areas of recruitment, training, support and integration. The support of volunteers should include four key areas: 1. Transfer of knowledge and professional competences 2. Individual support for personal development 3. Promotion of teamwork and social skills 4. Framework conditions (insurance cover, reimbursement of expenses) The implementation of these requirements should be carried out by specifically trained volunteer managers on the basis of a strong and motivating personal relationship. This strategy can be seen as a precondition for establishing a long-term relationship of the volunteer with the association, a successful local work, satisfied members and volunteers who perceive their work as satisfying and fulfilling. Silke Ssymank Deputy managing director Rheumatism League Baden-Württemberg e.V., Germany <h3>Disclosure of Interest</h3> None declared
AB0485 Primary antiphospholipid syndrome: maternal and fetal outcome
Authors: C Otaduy, PB Alba, CA Gobbi, A Alvarez, A Albiero, EH Albiero, ML Propato, MA Yorio
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Antiphospholipid antibodies (APLAs) have been associated with pregnancy loss and other obstetric complications, such as pre-eclampsia, fetal growth restriction and preterm delivery. <h3>Objectives</h3> The purpose of this work is to evaluate maternal and fetal pregnancy outcome in Primary Antiphospholipid Syndrome (PAPS). <h3>Methods</h3> We retrospectively studied PAPS patients according to Sydney Criteria who are attended to Materno Neonatal Hospital during the last 8 years. We evaluated demographic, obstetric and thrombotic clinical data. Maternal complications were evaluated: Preeclampsia, HELLP, Gestational Diabetes, Premature rupture of fetal membranes, arterial and venous thrombosis, mortality, the way of end of pregnancy, and others. Fetal outcome was evaluated as live birth, gestational age and weight at birth. <h3>Results</h3> 96 pregnancies in 68 patients were included. Maternal mean age was 30,75 years old, 84% were from Cόrdoba city, 70.5% did not have health insurance, and they have mean previous pregnancies of 4 with 1 live birth. Maternal complications were: Pre eclampsia in 12 patients (12.5%), Preterm delivery in 6 patients (6.25%), Premature rupture of fetal membranes in 8 (8.33%), Gestational Diabetes in 7 (7.29%), Arterial Thrombosis in 2 (2.08%), Venous thrombosis in 3 (3.12%). 33,69% have normal labour and 66,33% cesarean section. 86% of patients have live birth with mean gestational age of 36 weeks with mean weight at birth of 2.558 g and 73% of patients according to gestational age. <h3>Conclusions</h3> PAPS pregnancies patients had a good maternal and fetal outcome in this study. <h3>References</h3> Bertolaccini ML, Sanna G2 Recent advances in understanding antiphospholipid syndrome. F1000Res. 2016 Dec 22;5:2908. doi: 10.12688/f1000research.9717.1. eCollection 2016. Pelusa HF, Pezzarini E, Basiglio CL, Musuruana J, Bearzotti M, Svetaz MJ, Daniele SM, Bottai H, Arriaga SM. Antiphospholipid and antioangiogenic activity in females with recurrent miscarriage and antiphospholipid syndrome.Ann Clin Biochem. 2016 Sep 16. pii: 0004563216672248. [Epub ahead of print. Moroni G, Doria A, Giglio E, Tani C, Zen M, Strigini F, Zaina B, Tincani A, de Liso F, Matinato C, Grossi C, Gatto M, Castellana P, Limardo M, Meroni PL, Messa P, Ravani P, Mosca M. Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study.J Autoimmun. 2016 Nov;74:6–12. doi: 10.1016/j.jaut.2016.07.010. Epub 2016 Aug 2. <h3>Acknowledgements</h3> We are grateful whit Secyt subsidy UNC. <h3>Disclosure of Interest</h3> None declared
Nanobiomedicine: Protein Coating of DNA Nanostructures for Enhanced Stability and Immunocompatibility (Adv. Healthcare Mater. 18/2017)
Authors: Henni Auvinen, Hongbo Zhang, None Nonappa, Alisa Kopilow, Elina H. Niemelä, Sami Nummelin, Alexandra Correia, Hélder A. Santos, Veikko Linko, Mauri A. Kostiainen
Journal: Advanced Healthcare Materials (2017)

DNA origami nanostructures (purple double helix) can be coated with serum albumin proteins (green) to improve origami stability against DNA digesting enzymes, enhance delivery rates and, importantly, suppress the immune response. In article number 1700692, Henni Auvinen, Veikko Linko, Mauri Kostiainen, and co-workers present a straightforward and modular coating strategy that can bring DNA origami–based drug delivery vehicles and nanodevices closer to clinical applications.
Current status and strategies for hepatitis B control in Korea
Authors: Eun Ju Cho, Sung Eun Kim, Ki Tae Suk, Jihyun An, Soung Won Jeong, Woo Jin Chung, Yoon Jun Kim
Journal: Clinical and Molecular Hepatology (2017)

Hepatitis B virus (HBV) infection is the most common cause of chronic liver diseases in Korea. After the introduction of the universal HBV vaccination program, the prevalence of hepatitis B surface antigen was markedly reduced, and Korea is now classified as an area of intermediate endemicity for HBV. However, there are still hurdles for elimination of hepatitis B, such as immunoprophylaxis failure against vertical transmission, occurrence of acute hepatitis B among peoples who did not have vaccination at younger age, and rapid increase of immigrant populations from HBV endemic areas. To achieve the World Health Organization goal of viral hepatitis elimination by 2030 in Korea, we suggest comprehensive policies for more effective control of hepatitis B as following: i) insurance coverage for antiviral prophylaxis in mothers with high viremia, ii) screening for hepatitis B seromarkers and catch-up HBV vaccinations of susceptible persons with hepatitis B, iii) establishment of an independent 'viral hepatitis sector' in Centers for Disease Control & Prevention to organize and execute comprehensive strategy for management of viral hepatitis, iv) encourage of management of HBV infection in immigrant populations, v) national campaign to promote awareness of hepatitis B.
Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction
Authors: Maarit J. Korhonen, Jennifer G. Robinson, Izabela E. Annis, Ryan P. Hickson, J. Simon Bell, Juha Hartikainen, Gang Fang
Journal: Journal of the American College of Cardiology (2017)
THU0526 Short and long-term follow-up of tocilizumab for severe juvenile idiopathic arthritis-associated uveitis
Authors: N Vegas-Revenga, V Calvo-Río, M Santos-Gόmez, I Calvo, M González-Fernández, B Lόpez-Montesinos, M Mesquida, A Adan, M Hernández, O Maíz, A Atanes, B Bravo, C Modesto, G Díaz-Cordovés, N Palmou-Fontana, J Loricera, M González-Vela, R Demetrio-Pablo, L Domínguez-Casas, C Fernández-Díaz, J Hernández, M González-Gay, R Blanco
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> To assess the efficacy of tocilizumab (TCZ) at short and long term follow-up for severe juvenile idiopathic arthritis-associated uveitis. <h3>Methods</h3> Multicentre study of 25 patients who had inadequate response to traditional treatment with corticosteroids and at least one conventional immunosuppressive drug including biological therapy. The outcome variables were the degree of inflammation, visual acuity and macular thickness. The results are expressed as mean±SD for normally distributed variables, or median [IQR] when are not. Comparison of continuous variables was performed using the Wilcoxon test. <h3>Results</h3> We studied 25 patients (21 women/4 men); mean age 18.6±8.3. Uveitis was bilateral in 22. JIA subsets were oligoarthritis (n=17), polyarthritis (5), psoriatic (2) and enthesitis-related arthritis (1). Ocular sequelae at TCZ onset were cataracts (13), glaucoma (7), synechiae (10), band keratopathy (12), maculopathy (9), and amblyopia (5). Pattern of uveitis was: anterior (17), panuveitis (4), intermediate (2) and posterior (2). Before TCZ, they had received corticosteroids, conventional immunosuppressive drugs and biologics, including adalimumab (24), etanercept (8), infliximab (7), abatacept (6), rituximab (2), anakinra (1), and golimumab (1). TCZ dosage regimen was 8 mg/kg IV/4 weeks (21), every 2 weeks (2), every 8 weeks (1), or 2.9 mg/kg sc every week (1). All outcome variables showed a rapid and maintained improvement (Table 1) after a follow up of one year (n=21), 2 years (n=11), and 3 years (n=5). A reduction in the daily median dose of prednisone from 10 mg [0–15 mg] to 0 [0–0 mg] in 3 years, (p&lt;0.05) was observed. After a median follow-up of 20.5±11.7 months in 4 patients, the interval between TCZ doses was increased to 5 weeks (n=2), 6 weeks (1) and 7 weeks (1) because of remission. TCZ had to be withdrawn due to articular inefficiency (1) or articular and ocular inefficiency (1). The main adverse effects were severe autoimmune thrombocytopenia, autoimmune anemia and thrombocytopenia, pneumonia, viral conjunctivitis and bullous impetigo in 1 patient each. <h3>Conclusions</h3> TCZ is useful at short and long term follow-up for severe Juvenile Idiopathic Arthritis-associated uveitis. It is possible to optimize the TCZ dose. <h3>Disclosure of Interest</h3> None declared